|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bioinformatic analyses were utilized to define the expression of MYC-regulated genes in human colon cancer and metabolomics analyses were used to identify pathways regulated by LEF1 in MYC expressing cells.
|
31623618 |
2019 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We demonstrate that miR26b expression is a potent inhibitor of colon cancer cell proliferation and significantly decreases LEF1 expression.
|
24785257 |
2014 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A total of 106 colon cancer and matched paratumorous normal tissues were used to assess LEF1 expression using immunohistochemistry and qRT-PCR.
|
24098538 |
2013 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The role of different isoforms of LEF-1 on the growth of human colon carcinoma cell lines (SW480 and HT-29) was studied using various in vitro and in vivo assays.
|
22639890 |
2012 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A role for YY1 in repression of dominant negative LEF-1 expression in colon cancer.
|
20525792 |
2010 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that the biological outcome of aberrant LEF1 activation in colon cancer is directed by differential promoter activation and repression.
|
16809766 |
2006 |
|
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently, alterations of LEF-1 isoforms distribution have been described in colon cancer.
|
15756419 |
2005 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We suggest that the MYCBP gene can be a direct target of beta-catenin/LEF-1 pathway through its LEF-1 binding site(s) in the MYCBP promoter, and that MYCBP up-regulation in colon carcinoma cell may play a co-activator role of c-MYC.
|
15979100 |
2005 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here we show that the regulation of the expression of this enzyme in a colon cancer cell line, and in patients, is associated with overexpression of the Wnt pathway-associated proteins, Pontin52/TIP49a and LEF-1.
|
14675489 |
2003 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our findings identify LEF-1 as key regulator of beta-catenin nuclear localization and stability and suggest that overexpression of LEF-1 in colon cancer and melanoma cells may contribute to the accumulation of oncogenic beta-catenin in the nucleus.
|
11986304 |
2002 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Nr-CAM and LEF-1 expression was elevated in human colon cancer tissue and cell lines and in human malignant melanoma cell lines but not in melanocytes or normal colon tissue.
|
12183361 |
2002 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we used HCT-15 colon carcinoma and NIH 3T3 fibroblasts as models to investigate the effects of a phosphotyrosine phosphatase (PTPase) inhibitor on the localization of beta-catenin, the binding affinity to LEF-1 (Lymphoid Enhancer Factor), and on LEF-1-dependent transactivation function.
|
11401329 |
2001 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We report here that LEF1 is a new type of target gene ectopically activated in colon cancer.
|
11326276 |
2001 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Recent implications for beta-catenin signaling in cancer prompted us to examine colon cancer cell lines for the expression of LEF-1, a transcription factor that binds to beta-catenin.
|
9419974 |
1997 |